Author

Elli Narvi

Observed names: E Narvi, E. Narvi, Elli Veistinen

Institution: Orion Corporation (Finland)

Observed institutions: University of Turku, University of Eastern Finland, Karolinska Institutet, Orion Corporation (Finland), Turku Centre for Biotechnology, VTT Technical Research Centre of Finland

ORCID: 0000-0002-1468-5587

Observed ORCID: 0000-0002-1468-5587

OpenAlex ID: A5086079745

Loss of Pax5 Promotes Plasma Cell Differentiation

2006 · Kalle-Pekka Nera, Pekka Kohonen, et al. · Immunity · 244

PDF

Altered TUBB3 expression contributes to the epothilone response of mitotic cells

2013 · E Narvi, K Jaakkola, et al. · British Journal of Cancer · 56

PDF

Ikaros has a crucial role in regulation of B cell receptor signaling

2006 · Kalle‐Pekka Nera, Jukka Alinikula, et al. · European Journal of Immunology · 41

PDF

Aiolos Controls Gene Conversion and Cell Death in DT40 B Cells

2007 · E. Narvi, K.‐P. Nera, et al. · Scandinavian Journal of Immunology · 29

Both normal and leukemic B lymphocytes express multiple isoforms of the humanAiolos gene

2001 · Jussi Liippo, Kalle-Pekka Nera, et al. · European Journal of Immunology · 28

Ex vivo modeling of precision immuno-oncology responses in lung cancer

2024 · Bassel Alsaed, Johannes Smolander, et al. · Science Advances · 18

PDF

Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin

2018 · Elli Narvi, Katri Vaparanta, et al. · Scientific Reports · 14

PDF

Reduced levels of Dusp3/Vhr phosphatase impair normal spindle bipolarity in an Erk1/2 activity‐dependent manner

2016 · Mahesh Balasaheb Tambe, Elli Narvi, et al. · FEBS Letters · 12

PDF

Identification of fibroblast growth factor-8b target genes associated with early and late cell cycle events in breast cancer cells

2012 · E.M. Nilsson, L.J.S. Brokken, et al. · Molecular and Cellular Endocrinology · 11

Centmitor-1, a Novel Acridinyl-Acetohydrazide, Possesses Similar Molecular Interaction Field and Antimitotic Cellular Phenotype as Rigosertib, ON 01910.Na

2014 · Jenni H.E. Mäki-Jouppila, Leena J. Laine, et al. · Molecular Cancer Therapeutics · 5

Immunomodulatory Synthetic Glycocluster Molecule Prevents Melanoma Growth In Vivo

2024 · Meija Honkanen, Elli Narvi, et al. · ChemBioChem · 3

Bursa of Fabricius

2005 · Elli Veistinen, Olli Lassila · Wiley eBooks · 3

Abstract C059: Development of a Differentiated, Best-in-Class Oral Cbl-b Inhibitor with Robust Immune Activation and Favourable Safety for Cancer Immunotherapy

2025 · Chandregowda Venkateshappa, Sandeep Patil, et al. · Molecular Cancer Therapeutics

Abstract 914: Differential expression of Cbl-b in tumor infiltrating immune cells in patients with solid tumors

2025 · Elli Narvi, Reetta Virtakoivu, et al. · Cancer Research

190P Ex vivo modeling of precision immuno-oncology responses in lung cancer

2024 · B. Alsaed, J. Smolander, et al. · Immuno-Oncology Technology

PDF

Abstract 4223: The dual immunestimulatory and immunesuppressive role of MRC5 fibroblast cells in 3D coculture with T cells and tumor cells

2024 · Ilona Arnkil, Can Hekim, et al. · Cancer Research

1044 High dose of rhIL-10 enhances CD8 T cell and NK cell mediated tumor cell killing in vitro

2023 · Elli Narvi, Anna Brunell, et al. · Journal for ImmunoTherapy of Cancer

PDF

Data from Centmitor-1, a Novel Acridinyl-Acetohydrazide, Possesses Similar Molecular Interaction Field and Antimitotic Cellular Phenotype as Rigosertib, ON 01910.Na